HKU Scholars Hub: Browsing DSpace

Browsing by Author Yiu, WH

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 34 to 53 of 60 < previous next >

Title	Author(s)	Issue Date	Views
Patients’ and clinicians’ expectations on integrative medicine Services for Diabetes: a focus group study Journal:BMC Complementary Medicine and Therapies	Chan, KW Lee, PW Leung, CPS Chan, GCW Yiu, WH Cheung, HM LI, B LOK, SWY LI, H XUE, R Chan, LYY Leung, JCK Lam, TP Lai, KN Tang, SCW	2020	37
Potential Therapeutic Targets of Rehmannia Formulations on Diabetic Nephropathy: A Comparative Network Pharmacology Analysis Journal:Frontiers in Pharmacology	Chan, KW Yu, KY Yiu, WH XUE, R LOK, WY LI, H ZOU, Y MA, J Lai, KN Tang, SCW	2022
PRAgmatic Clinical Trial Design of Integrative MediCinE (PRACTICE): A Focus Group Series and Systematic Review on Trials of Diabetes and Kidney Disease Journal:Frontiers in Medicine	Chan, KW Lee, PW Leung, CPS Law, YK Gao, L Chan, GCW Yiu, WH Lam, TP Tang, SCW	2021
Protective role of kallistatin in renal fibrosis via modulation of Wnt/β-catenin signaling Journal:Clinical Science	Yiu, WH Li, Y Lok, SWY Chan, KW Chan, LYY Leung, JCK Lai, KN Tsu, JHL Chao, J Huang, XR Lan, HY Tang, SCW	2021	39
Protein overload induces renal proximal tubular epithelial cell apoptosis by down-regulating WNT/β-catenin signalling Proceeding/Conference:Journal of the American Society of Nephrology	Wong, DWL Yiu, WH Wu, H Li, R Leung, JCK Chan, LYY Lai, KN Tang, SCW	2013
Role of bone morphogenetic protein-7 (BMP7) in diabetic tubulopathy Proceeding/Conference:Journal of the American Society of Nephrology	Li, R Yiu, WH Wu, H Lin, M Wong, DWL Chan, LYY Leung, JCK Lai, KN Tang, SCW	2013	50
Role of bone morphogenetic protein-7 in renal fibrosis Journal:Frontiers Physiology	LI, R Yiu, WH Tang, SCW	2015	59
Role of Renal Tubular Wnt/Beta-catenin in Proteinuric Kidney Proceeding/Conference:Hong Kong Society of Nephrology Annual Scientific Meeting 2018	Yiu, WH	2018	6
Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy – Interim analysis of an add-on, randomised, controlled, multi-centre, open-label pragmatic trial Proceeding/Conference:International Congress of Chinese nephrologists	Chan, KW Kwong, ASK Lui, SL Ip, TP Chan, GCW Cowling, BJ Yiu, WH Wong, WLD LI, B LI, Y Feng, Y Tan, KCB Chan, YY Leung, JCK Lai, KN Tang, SCW	2017	106
Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy – Preliminary results of an add-on, randomised, controlled, multi-centre, open-label pragmatic trial Proceeding/Conference:Journal of the American Society of Nephrology	Chan, KW Kwong, ASK Lui, SL Ip, TP Chan, GCW Cowling, BJ Yiu, WH Wong, WLD Li, B Li, Y Feng, Y Tan, KCB Chan, YY Leung, JCK Lai, KN Tang, SCW	2017
Semi-individualised Chinese medicine treatment as an adjuvant management for diabetic nephropathy: a pilot add-on, randomised, controlled, multicentre, open-label pragmatic clinical trial Journal:BMJ Open	Chan, KW Ip, TP Kwong, ASK Lui, SL Chan, GCW Cowling, BJ Yiu, WH Wong, DWL Liu, Y Feng, Y Tan, KCB Chan, LYY Leung, JCK Lai, KN Tang, SCW	2016	89
Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy: Interim analysis of an add-on, randomised, controlled, multi-centre, open-label pragmatic trial Proceeding/Conference:Hong Kong Medical Journal	Chan, KW Kwong, ASK Lui, SL Ip, TP Chan, GCW Cowling, BJ Yiu, WH Wong, WLD Li, B Li, Y Feng, Y Tan, KCB Chan, YY Leung, JCK Lai, KN Tang, SCW	2018	94
Semi-individualised Chinese medicine treatment for diabetic kidney disease - from users' perspectives to SCHEMATIC trial interim result and potential mechanism. Proceeding/Conference:Good Practice in Traditional Chinese Medicine Research Association, London.	Chan, KW Kwong, AS Chan, GC Leung, CP Yiu, WH Lui, SL Ip, TP Cowling, BJ Wong, DW Li, B Li, Y Feng, Y Chan, LY Leung, JCK Tan, KCB Wong, VC Lai, KN Tang, SCW	2017	60
Semi-individualised Chinese Medicine Treatment for Diabetic Kidney Disease – From users’ perspectives to SCHEMATIC trial interim result and potential mechanisms Proceeding/Conference:Advances in Integrative Medicine	Chan, KW Kwong, ASK Chan, GCW Leung, CPS Yiu, WH Lui, SL Ip, TP Cowling, BJ Wong, WLD Li, B Li, Y Feng, Y Chan, YY Leung, JCK Tan, KCB Wong, CWV Lai, KN Tang, SCW	2019	123
Spleen Tyrosine Kinase Inhibition Ameliorates Tubular Inflammation in IgA Nephropathy Journal:Frontiers in Physiology	Yiu, WH Chan, KW Chan, LYY Leung, JCK Lai, KN Tang, SCW	2021
Spleen Tyrosine Kinase Inhibitor Ameliorates Tubular Inflammation in IgA Nephropathy. Proceeding/Conference:Journal of the American Society of Nephrology	Yiu, WH Wong, WLD Wu, H Chan, KW Liu, Y Chan, LYY Leung, JCK Lai, KN Tang, SCW	2016	47
The Expectation, Concern, and Experience of patients towards Integrative Chinese-western Medicine for Diabetic Kidney Disease: A qualitative study Proceeding/Conference:Journal of the American Society of Nephrology	Chan, KW Leung, C Chan, GCW Yiu, WH Wong, WLD Li, B Li, Y Chan, YY Leung, JCK Tang, SCW	2017
The PAR-1 antagonist Vorapaxar ameliorates kidney injury and tubulointerstitial fibrosis Journal:Clinical Science	Lok, SWY Yiu, WH Li, H Xue, R Zou, Y Li, B Chan, KW Chan, LYY Leung, JCK Lai, KN Tang, SCW	2020	39
The PAR-1 Antagonist Vorapaxar Protects Against AKI To CKD Transition Proceeding/Conference:Journal of the American Society of Nephrology	LOK, WY Yiu, WH Chan, LYY Leung, JCK Lai, KN Tang, SCW	2020	8
Thrombin induces Epithelial-Mesenchymal Transition through the activation of PAR-1 in Tubular Epithelial Cells Proceeding/Conference:Journal of the American Society of Nephrology	Yiu, WH Wong, WLD Leung, JCK Chan, LYY Lai, KN Tang, SCW	2014	60

Showing results 34 to 53 of 60 < previous next >